Evidence-Based Insights. No Hype.
Compound analysis, regulatory updates, and quality assurance guidance. All content references peer-reviewed sources. No therapeutic claims.
Understanding Triple Agonism: How Retatrutide Differs from Semaglutide and Tirzepatide
A detailed comparison of single, dual, and triple receptor agonist mechanisms. Reviewing the published Phase 2 and Phase 3 clinical data and the role of glucagon receptor activation.
How to Read a Certificate of Analysis: A Researcher’s Guide
What each section of a COA means, how to interpret HPLC chromatograms, mass spectrometry results, and endotoxin data. What to look for and what constitutes a red flag.
BPC-157: What the Preclinical Evidence Actually Shows
An honest review of the published BPC-157 literature. Mechanism of action, tissue-specific findings, and the important limitations of the current evidence base.
The Australian Research Peptide Landscape in 2026
Schedule 4 classification, the Poisons Standard, Appendix D listings, and what Research Use Only actually means under Australian law. A regulatory overview for researchers.
GLP-1, GIP, and Glucagon: Receptor Biology and Research Applications
A primer on the three incretin and counter-regulatory receptors driving the current wave of metabolic peptide research. Downstream signalling cascades and tissue distribution.
TB-500 and BPC-157: Distinct Mechanisms in Tissue Research
Why these two peptides are investigated together despite acting through different molecular pathways. Actin dynamics versus nitric oxide signalling in preclinical models.
Access the Compounds
All compounds referenced in our journal are available with batch-specific COA.